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Abstract 
 
,-Disubstituted alkenyl amino acid derivatives (e.g. Fmoc-S5-OH) are valuable monomers 
in the construction of stapled peptide derivatives. Synthetic access to these is possible using 
the Ni-[(Benzylprolyl)amino]benzophenone (BPB) complex as a chiral auxiliary. We discuss 
a reappraisal of the use of this, and demonstrate that epimerisation of the proline -center 
occurs during formation of the complex, leading to erosion in the enantiomeric excess of the 
final product. Modified conditions have been developed, providing the target compounds in 
high enantiomeric excess. 
 
Introduction 
 
The synthesis of homochiral, non-proteinogenic amino acid derivatives is an important 
objective for many applications in the area of peptide science.1,2 First introduced by 
Verdine,3 the α,α-disubstituted alkenyl amino acids 1 – 4 (Figure 1) are pivotal building 
blocks in the construction of peptide staples, which represent stabilised epitopes of larger 
protein assemblies designed to mimic -helical secondary structure.4 These peptide 
derivatives have found utility in a number of biological applications, including as drug 
candidates for clinical studies. Accordingly, having access to robust methods for the 
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synthesis of the requisite amino acid monomers used to construct target peptide staples is a 
pivotal consideration in enabling the preparation of these biologically useful entities.  
 
Figure 1.  Verdine amino acids used for construction of peptide staples. 
 
To this end, a number of chiral auxiliary based approaches to 1 and related derivatives have 
been reported.3,5,6 From this set, an auxiliary which has been of particular interest to a 
number of groups has been the Ni-BPB based system (5)7 and related analogues which 
have been used in the construction of both mono-8 and α,α-disubstituted alkenyl9,10 amino 
acids exemplified by 1 and its derivatives. Application of compound 5 in this context is 
attractive given the predictable sense of stereoinduction imparted by the proline –centre of 
the auxiliary (Figure 2),7 and the fact that large scale synthesis of the Schiff-base complex 
(up to 1 kg) has been reported.11 
 
 
Figure 2. Mnemonic developed to rationalise stereoinduction. 
 
As part of an on-going medicinal chemistry effort in our laboratories utilising peptide staples, 
we sought to prepare alkenyl amino acids 1 – 4 using the Ni-BPB Schiff base complexes 
given the apparently robust precedence already established. In this report, however, we 
report the epimerisation of the proline under conditions used to facilitate formation of the 
Schiff base complex resulting in sub-optimal measured enantiomeric excess of the final 
Fmoc amino acid product. Based on these observations, we have then developed modified 
procedures for complex formation, enabling synthesis target amino acid derivatives in high 
enantiomeric excess. 
 
Our synthetic approach commenced through formation of the auxiliary using a combination 
of reported procedures11,12 to form the Schiff base complex 5 (Scheme 1). In particular, the 
final complexation step proved difficult to perform on larger scale without compromising 
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yield. It was found that extended reaction times and increasing the equivalents of KOH used 
was necessary to achieve high yields. 
 
Scheme 1. Access to the BPB auxiliary. 
 
With adequate quantities of the BPB auxiliary in hand, we next turned our attention to the 
alkylation step. More recent reports8,9 had suggested that this could be capricious in nature, 
therefore a focused optimisation was undertaken. From consideration of the primary 
literature, some of the highest yields for enantioselective alkylation with haloalkenes had 
been achieved using sodium hydroxide.9,13  The published conditions employing sodium 
hydroxide as a base used dry acetonitrile and DMF as solvents, therefore acetonitrile was 
chosen for initial screening as the resulting work-up and isolation was reasoned to be less 
problematic. 5-bromopentene was selected as the substrate due to its commercial 
availability and success reported elsewhere.9,10 Finally, the reaction temperature was 
maintained at ambient as increasing the temperature was anticipated to lower the 
diastereomeric ratio. The results of this survey are reported in Table 1. 
 
The use of sodium hydroxide as a base was not successful (Entry 1), nor was potassium 
tert-butoxide in acetonitrile although traces of product could be observed when used in THF 
(Entries 2 and 3). Purifying potassium tert-butoxide by sublimation and addition of tetra-N-
butylammonium iodide (TBAI) as an additive gave modest isolated yields (Entry 4), whereas 
exchanging the electrophile for the corresponding alkyl iodide resulted in an increased yield, 
particularly when used in conjunction with TBAI (Entries 5 and 6). The precise reasons for 
the elevation in yield observed with TBAI are not clear, however, this could be attributable to 
the tertiary butylammonium cation minimizing enolate aggregation which could otherwise 
supress reactivity. The overall process reported compares favourably with previously 
reported conditions, where isolated yields of 55-68% were obtained.9,10 The diasteromeric 
ratio of compound 10 was found to be in excess of 98% as determined by 1H NMR, implying 
that the enolate alkylation had occurred in a stereoselective manner. 
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Table 1. Optimisation of alkylation of BPB auxiliary. 
 
 
 
 
 
 
 X Base Solvent Additive Reaction 
time 
Yield 10 
1 Br NaOH MeCN - 2 h No 
reaction 
2 Br tBuOK MeCN - 2 h No 
reaction 
3 Br tBuOK THF - 2 h Trace 
4 Br tBuOK 
(sub.) 
THF (dry) TBAI (0.1 
equiv)  
5 h 35% 
5 I tBuOK 
(sub.) 
THF (dry) - 5 h 43% 
6 I tBuOK 
(sub.) 
THF (dry) TBAI (0.1 
equiv)  
16 h 70% 
 
Having enabled optimal conditions for the synthesis of complex 10, we next sought to 
generate the free amino acid before subsequently installing the N-Fmoc protecting group, at 
which point the enantiomeric excess of the final product could be determined through chiral 
HPLC with UV-detection. Acidolysis of the complex proceeded smoothly using dilute HCl 
(Scheme 2), with the amino acid being isolated using ion exchange chromatography. 
Incorporation of the Fmoc group using 9-Fluorenylmethyl N-succinimidyl carbonate gave the 
final compound in acceptable yield following reverse phase purification. 
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Scheme 2. Hydrolysis and Fmoc protection of final alkenyl amino acid. 
 
However, despite the encouraging levels of diastereomeric purity of alkylated BPB complex 
10 observed using 1H NMR, this did not translate into appreciably high levels of enantiomeric 
purity when analysing Fmoc-S5-OH by chiral HPLC. This study indicated that the target 
amino acid was obtained in only 82% enantiomeric excess, which was deemed to be 
unsuitable for use in solid phase peptide synthesis. The cause of this apparent erosion in 
enantiomeric excess was initially not clear given the high diastereomeric purity of the 
precursor complex 10 and the predictable sense of stereoinduction associated with the BPB-
based auxiliary systems in general. Some insight into the precise reasons behind this 
disappointingly low level of enantiomeric excess was obtained through acquisition of a small 
molecule X-ray structure of complex 10 (Figure 3). 
 
 
Figure 3. X-ray diffraction derived structure of BPB-complex 10 showing presence of 
opposite enantiomer. 
 
The isolation of centrosymmetric crystals of complex 10 revealed that although this species 
was predominately a single diastereomer, a significant amount of both the corresponding 
enantiomers is present. This ultimately results in the lower than expected enantiomeric 
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excess observed. Although the single crystal shows a 1:1 mix of (R, R) and (S, S) 
complexes, the bulk must in fact be a scalemate given the higher enantiomeric excess (82%) 
observed by chiral HPLC of the final quaternary amino acid product.  
 
Formation of the (R, R) complex is a result of alkylation of the (R)-proline based auxiliary 
which arises through epimerisation of the -centre of the auxiliary during its synthesis. This 
observation is perhaps surprising as a lower enantiomeric excess of final amino acid 1 would 
be more likely be attributable to poor diastereocontrol during enolate alkylation rather than 
inherent issues with the auxiliary itself. Detection of the presence of the (R, R) complex is 
not possible by 1H NMR, however, chiral HPLC indicated the enantiomeric excess of 
complex 10 was 84% and is, therefore, in very close accord with the result obtained for 
Fmoc-S5-OH confirming that the alkylation step is indeed relatively diastereoselective in 
nature. It was then important to establish at what point in the preparation of the BPB auxiliary 
epimerisation of the proline center occurred. Development of a chiral HPLC assay to 
determine the enantiomeric excess of the immediate precursor 5 was not possible as this 
was likely to be a mixture of up to 4 diastereomers given the fact that DL-Ala is generally 
used in the complexation step as this center is enolised when the ,-disubstituted amino 
acid is prepared.  It was, however, possible to determine the enantiomeric excess for the 
benzophenone amide derivative 9 which was shown to have an ee of in excess of 98%, 
indicating that epimerisation of the proline derivative was not taking place during amide bond 
formation. From this result, it was inferred that the conditions used in the formation of the 
BPB-Ala complex 5 itself (prolonged treatment with base at elevated temperatures) were 
more than likely the cause of the erosion in chiral integrity of the auxiliary. 
 
Accordingly, the formation of complex 5 was re-examined, with particular focus on reaction 
time and stoichiometry of KOH used (Scheme 3). Employing shorter reaction times and 
using fewer equivalents of base added as a solution rather than a powder was successful in 
forming complex 10 in good yield. Subsequent alkylation using the conditions developed 
above and assessment of enantiomeric excess by chiral HPLC indicated that alkylated 
complex 10 was primarily a single enantiomer (94% ee), confirming that epimerisation of the 
auxiliary during its formation is largely responsible for the erosion in enantiomeric excess 
observed. Following acidolysis of the complex and installation of the Fmoc protecting group, 
measurement of enantiomeric excess of 1 indicated a superior ee of 92% (compared to the 
ee of 82% previously obtained in the preparation of this compound), consistent with what 
was observed for the alkylation step, and supporting the fact that high measured enantio- 
and diastereomeric ratios of complex 10 translated into a final product of near identical levels 
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of enantiopurity. The antipode 3 could also be prepared using the same route commencing 
from the (R)-BPB derived auxiliary 13 (prepared in an analogous fashion to the 
corresponding (S)-auxiliary), again with enantiomeric excess of alkylated complex 14 
translating to measured optical purity of the final amino acid Fmoc-R5-OH (3, Scheme 3). 
Based on all of the above, limiting the exposure of Ni-BPB complexes to base is crucial in 
maintaining the stereochemical integrity of the auxiliary in order to obtain amino acid 
products of appropriate optical purity. 
 
Scheme 3. Modified route to 1 and application to synthesis of 2. 
 
A corollary to the current work relates to recent reports14,15,16 using the BPB auxiliary to 
kinetically resolve or invert the stereochemistry of amino acids ligated to a Ni Schiff base 
complex. Both of these studies report conditions which involve prolonged treatment of BPB 
auxiliaries with base. In addition to this, a recent report from Li and co-workers17 indicate the 
choice of base being crucial when using a related BPP auxiliary for the synthesis of amino 
acids of the type 1 – 4, with tert-butoxide derived bases being optimal. These reports, 
together with consideration of our observations, some degree of caution therefore needs to 
be exercised in exposing Ni-BPB complexes to base as epimerisation of the proline may 
occur, leading to compromised optical purity of final products. 
 
In conclusion, through a combination of X-ray crystallographic input and chiral HPLC 
analysis, this study has shown that the variable nature of stereoinduction observed using Ni-
BPB complexes is not solely attributable to poor levels of facial control upon enolate 
alkylation of complexes such as 5 but is a consequence of epimerisation of the auxiliary 
itself.  We anticipate these findings will be of use in developing robust and scalable 
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syntheses of alkenyl amino acids 1 – 4 which are of value in the area of peptide staples, and 
may also impact on other applications of the BPB auxiliary as noted above. 
 
 
Experimental Section 
General Methods. All reagents and solvents were used as obtained unless otherwise 
stated. Purification was carried out according to standard laboratory methods.18 Thin layer 
chromatography was carried out using aluminium-backed silica plates which were analysed 
under 254 nm UV light or developed using potassium permanganate solution. Flash 
chromatography was carried out using prepacked silica cartridges. 1H NMR spectra were 
recorded at 400 or 500 MHz and 13C NMR spectra were recorded at 101 or 126 MHz, 
respectively. Chemical shifts are reported in ppm and coupling constants are reported in Hz 
with CDCl3 referenced at 7.27 (1H) and 77.23 ppm (13C), and DMSO referenced at 2.50 (1H) 
and 39.51 ppm (13C). Mass spectrometry data was generated using a TOF analyser at the 
University of Swansea, UK. Optical rotations were measured at 589 nm, with concentrations 
reported in g per 100 mL. Normal-phase chiral HPLC was carried out using a Chiralpak IA 
(Amylose tris(3,5-dimethylphenylcarbamate)) column at room temperature with a flow rate of 
1 mL/min. Analysis of Nickel complexes was achieved using an isocratic system of 40% IPA 
in hexane over 40 minutes. Chiral separation of Fmoc amino acids was achieved using a 
gradient of 5 – 20% IPA in hexane with a flow rate of 1 mL/min over 20 minutes. Strong 
cation exchange chromatography was carried out using sulfonic acid functionalised DOWEX 
resin, 50WX8 H-form. 1-iodopent-4-ene was prepared as previously reported.19 
 
Benzyl-L-proline hydrochloride (7)11 
To a round bottomed flask containing 2-propanol (60 mL) at 40 oC was added L-proline (10.0 
g, 86.6 mmol, 1 equiv.) and the reaction mixture stirred at this temperature until fully in 
solution. The reaction mixture was then cooled to 0 oC and KOH (19.5 g, 347 mmol, 4 
equiv.) was added and stirred for 5 minutes. Benzyl chloride (15 mL, 130 mmol, 1.5 equiv.) 
was added dropwise over 15 minutes, maintaining the temperature between 0 oC and 5 oC. 
Once addition was complete, the reaction mixture was heated to 40 oC and stirred for 17 h. 
Once complete, the reaction mixture was cooled to room temperature and acidified to pH 4 
with conc. HCl. DCM (150 mL) was added and the flask placed in the fridge overnight. The 
precipitate was then filtered off and the filtrate concentrated in vacuo. The residue was 
suspended in acetone to give a white solid. Filtration and washing with cold acetone afforded 
the title compound as a white solid (17.2 g, 82%). 
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νmax (neat):  3005, 2993, 2953, 1713, 1672, 1498 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 7.45 
– 7.42 (m, 2H), 7.40 – 7.32 (m, 3H), 5.12 (br s, 1H), 4.19 (d, 1H, J = 13.2 Hz), 3.91 (d, 1H, J 
= 13.2 Hz), 3.59 (dd, 1H, J = 6.0, 3.2 Hz), 3.20 – 3.15 (m, 1H), 2.81 – 2.74 (m, 1H), 2.24 – 
2.14 (m, 1H), 1.96 – 1.81 (m, 2H), 1.78 – 1.71 (m, 1H). 13C NMR (101 MHz, DMSO-d6 ): δ 
171.6, 134.8, 129.6, 128.4, 128.1, 65.8, 57.2, 53.1, 28.4, 22.6. HRMS: (C12H16O2N1) [M+H]+ 
requires 206.1176, found [M+H]+ 206.1175. [α]20D = -28.8 (c = 1, MeOH). 
 
 (S)-N-(2-benzoylphenyl)-1-benzylpyrrolidine-2-carboxamide (9)11 
To a round bottomed flask containing dry DCM (475 mL) under N2 was added 7 (34.5 g, 143 
mmol, 1 equiv.) to form a cloudy suspension. The reaction mixture was cooled to -20 oC 
using a mixture of ice and NaCl (1:3), giving (on average) an internal temperature of -5 oC.  
N-Methyl imidazole (31.8 mL, 399 mmol, 2.8 equiv.) was then added and stirred for 5 
minutes. Methanesulfonyl chloride (12.2 mL, 157 mmol, 1.1 equiv.) was then added slowly 
over 5 minutes, maintaining the internal temperature at between -5 oC to 0 oC. The reaction 
mixture was then left to stir at -5 oC to 0 oC for 30 minutes. 2-Aminobenzophenone (25.3 g, 
128 mmol, 0.9 equiv.) was then added and the reaction mixture left to stir at room 
temperature for 17 h. The reaction mixture was quenched with sat. NH4Cl and separated 
with DCM (3 x 400 mL). The organic layers were combined, dried and concentrated in vacuo 
to give the crude as a dark brown oil. The crude was then purified by silica chromatography 
(0-100% EtOAc in Pet. Ether 40/60) to give the title compound as a yellow solid (42.3 g, 
86%). 
νmax (neat): 3248, 2968, 2839, 2810, 1687, 1643, 1576, 1510, 1442 cm-1. 1H NMR (400 MHz, 
CDCl3): δ 11.54 (s, 1H), 8.59 (dd, 1H, J = 7.6, 1.2 Hz), 7.82 – 7.80 (m, 2H), 7.67 – 7.61 (m, 
1H), 7.57 – 7.45 (m, 4H), 7.41 – 7.39 (m, 2H), 7.18 – 7.15 (m, 3H), 7.13 – 7.09 (m, 1H), 3.95 
(d, 1H, J = 13.2 Hz), 3.62 (d, 1H, J = 13.2 Hz), 3.37 (dd, 1H, J = 5.2, 4.8 Hz), 3.27 – 3.22 (m, 
1H), 2.47 – 2.40 (m, 1H), 2.33 – 2.23 (m, 1H), 2.03 – 1.96 (m, 1H), 1.90 – 1.76 (m, 2H). 13C 
NMR (101 MHz, CDCl3): δ 197.5, 174.1, 138.7, 138.1, 137.7, 132.9, 132.1, 132.0, 129.6, 
128.7, 127.8, 127.7, 126.6, 124.9, 121.7, 121.1, 67.8, 59.4, 53.4, 30.5, 23.7. HRMS: 
(C25H25O2N2) [M+H]+ requires 385.1911, found [M+H]+ 385.1908. [α]20D = -106.7 (c = 1, 
MeOH). ee = >98 % by chiral HPLC, retention time = 11.95 min. 
 
 (R)-N-(2-benzoylphenyl)-1-benzylpyrrolidine-2-carboxamide (12)11 
To a round bottomed flask containing dry DCM (50 mL) under N2 was added benzyl-L-
proline hydrochloride (7.4 g, 30.6 mmol, 1 equiv.) to form a cloudy suspension. The reaction 
mixture was cooled to -20 oC using a mixture of ice and NaCl (1:3), giving (on average) an 
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internal temperature of -5 oC.  N-Methyl imidazole (9.8 mL, 85.7 mmol, 2.8 equiv.) was then 
added and stirred for 5 minutes. Methanesulfonyl chloride (2.4 mL, 33.6 mmol, 1.1 equiv.) 
was then added slowly over 5 minutes, maintaining the internal temperature at between -5 
oC to 0 oC. The reaction mixture was then left to stir at -5 oC to 0 oC for 30 minutes. 2-
Aminobenzophenone (138) (5.4 g, 27.5 mmol, 0.9 equiv.) was then added and the reaction 
mixture left to stir at room temperature for 17 h. The reaction mixture was quenched with sat. 
NH4Cl and separated with DCM (3 x 100 mL). The organic layers were combined, dried and 
concentrated in vacuo to give the crude as a dark brown oil. The crude was then purified by 
silica chromatography (0-100% EtOAc in Pet. Ether 40/60) to give the title compound as a 
yellow solid (9.0 g, 85%). 
νmax (neat): 3250, 2963, 2822, 1688, 1640, 1515, 1442 cm-1; 1H NMR (400 MHz, CDCl3): δ 
11.52 (s, 1H), 8.58 (dd, 1H, J = 7.6, 0.8 Hz), 7.80 – 7.78 (m, 2H), 7.64 – 7.60 (m, 1H), 7.56 – 
7.49 (m, 4H), 7.40 – 7.37 (m, 2H), 7.17 – 7.14 (m, 3H), 7.12 – 7.08 (m, 1H), 3.93 (d, 1H, J = 
12.8 Hz), 3.61 (d, 1H, J = 12.8 Hz), 3.35 – 3.31 (dd, 1H, J = 5.2, 4.8 Hz), 3.23 – 3.21 (m, 
1H,), 2.45 – 2.40 (m, 1H), 2.30 – 2.22 (m, 1H), 2.00 – 1.96 (m, 1H), 1.83 – 1.77 (m, 2H); 13C 
NMR (101 MHz, CDCl3 ): δ 197.5, 174.2, 138.7, 138.1, 137.7, 132.9, 132.1, 132.0, 129.6, 
128.7, 127.8, 127.7, 126.6, 124.9, 121.7, 121.1, 67.8, 59.4, 53.4, 30.5, 23.7; HRMS: 
(C25H25O2N2) [M+H]+ requires 385.1911, found [M+H]+ 385.1910; [α]20D = +106.6 (c = 1, 
MeOH); ee = >98 % by chiral HPLC, retention time 11.42 min. 
 
(S)-Ni(II)-Ala-BPB (5)11 
To a round bottomed flask containing MeOH (70 mL) under N2 was added 9 (7.68 g, 20.0 
mmol, 1 equiv.), DL-Alanine (3.60 g, 40.0 mmol, 2 equiv) and Ni(NO3)2.6H2O (11.6 g, 40.0 
mmol, 2 equiv.) and the contents heated to 40 oC. A solution of KOH (7.84 g, 140 mmol, 7 
equiv.) in MeOH (30 mL) was added dropwise to the reaction vessel over 10 minutes. Once 
addition was complete, the reaction mixture was heated to 50 oC and left to react for 2 h. 
The reaction was cooled to room temperature and neutralised with conc. acetic acid. Water 
(400 mL) and DCM (200 mL) were added to the reaction vessel and left to stir overnight. The 
mixture was then separated with DCM (3 x 300 mL) and the organic layers combined, dried 
and concentrated in vacuo to give the crude product as a red oil. The crude material was 
then purified by silica chromatography (0-100% EtOAc in Pet. Ether 40-60, 0-5% MeOH in 
EtOAc) to give the title compound as a bright red solid (7.55 g, 74%). 
νmax (neat): 2976, 2872, 1678, 1622, 1591, 1440 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.12 – 
8.06 (m, 3H), 7.54 – 7.44 (m, 3H), 7.39 (t, 2H, J = 8.4 Hz), 7.27 – 7. 12 (m, 3H), 6.96 (d, 1H, 
J = 7.6 Hz), 6.68 – 6.61 (m, 2H), 4.43 – 4.40 (m, 1H), 3.91 (q, 1H, J = 7.2 Hz), 3.75 – 3.69 
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(m, 1H), 3.56 (d, 1H, J = 12.8 Hz), 3.53 – 3.47 (m, 1H), 2.77 – 2.72 (m, 1H), 2.59 – 2.51 (m, 
1H), 2.25 – 2.18 (m, 1H), 2.11 – 2.04 (m, 1H), 1.61 – 1.59 (m, 3H). 13C NMR (101 MHz, 
CDCl3 ): 180.3, 170.1, 170.1, 142.0, 133.4, 133.3, 133.0, 131.9, 131.4, 129.6, 128.8, 128.7, 
127.4, 127.1, 126.3, 123.8, 120.7, 70.1, 66.4, 63.0, 57.2, 30.7, 24.0, 21.7. 1C not observed. 
HRMS: (C28H28O3N3Ni) [M+H]+ requires 512.1479, found [M+H]+ 512.1467. [α]20D = +2669 (c 
= 0.03, MeOH).  
 
 (R)-Ni(II)-Ala-BPB (13) 
To a round bottomed flask containing MeOH (20 mL) under N2 was added 1211 (2.0 g, 5.2 
mmol, 1 equiv.), DL-Alanine (0.93 g, 10.4 mmol, 2 equiv) and Ni(NO3)2.6H2O (3.02 g, 10.4 
mmol, 2 equiv.) and the contents heated to 40 oC. A solution of KOH (2.04 g, 36.4 mmol, 7 
equiv) in MeOH (10 mL) was added dropwise to the reaction vessel over 10 minutes. Once 
addition was complete, the reaction mixture was heated to 50 oC and left to react for 2 h. 
The reaction was cooled to room temperature and neutralised with conc. acetic acid. Water 
(100 mL) and DCM (50 mL) were added to the reaction vessel and left to stir for 3 h. The 
mixture was then separated with DCM (3 x 100 mL) and the organic layers combined, dried 
and concentrated in vacuo to give the crude product as a red oil. The crude material was 
then purified by silica chromatography (0-100% EtOAc in Pet. Ether 40-60, 0-5% MeOH in 
EtOAc) to give the title compound as a bright red solid (2.36 g, 88%). 
νmax (neat): 2978, 2872, 1678, 1624, 1591, 1438 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.12 – 
8.07 (m, 3H), 7.55 – 7.44 (m, 3H), 7.38 (t, 2H, J = 8.4 Hz), 7.31 – 7. 15 (m, 3H), 7.14 – 7.11 
(m, 1H), 6.95 (d, 1H J = 7.6 Hz), 6.69 – 6.61 (m, 2H), 4.44 – 4.41 (m, 1H), 3.91 (q, 1H, J = 
7.2 Hz), 3.76 – 3.68 (m, 1H), 3.55 (d, 1H, J = 12.8 Hz), 3.51 – 3.43 (m, 1H,), 2.77 – 2.71 (m, 
1H), 2.59 – 2.48 (m, 1H), 2.26 – 2.18 (m, 1H), 2.11 – 2.04 (m, 1H), 1.61 – 1.59 (m, 3H). 13C 
NMR (101 MHz, CDCl3 ): 180.4, 180.3, 170.2, 142.0, 133.4, 133.3, 133.0, 132.0, 131.4, 
129.6, 128.9, 128.4, 127.4, 127.1, 126.4, 123.8, 120.7, 70.0, 66.5, 63.0, 57.2, 30.7, 24.0, 
21.8. HRMS: (C28H28O3N3Ni) [M+H]+ requires 512.1479, found [M+H]+ 512.1470. [α]20D = -
2043 (c = 0.03, MeOH).  
 
 (S)-Ni(II)-S5-BPB (10) 
To a dry round bottomed flask containing dry THF (25 mL) was added 5 (1.0 g, 1.9 mmol, 1 
equiv.) and cooled to 0 oC under N2. TBAI (72 mg, 0.20 mmol, 0.1 equiv.) and sublimed 
tBuOK (547 mg, 4.90 mmol, 2.5 equiv.) were added and the mixture left to stir for 5 minutes. 
5-iodopentene (957 mg, 4.90 mmol, 2.5 equiv.) was added dropwise over 5 minutes and the 
reaction mixture left to stir at room temperature for 17 h. The reaction mixture was quenched 
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with 0.1 M HCl and separated with DCM (3 x 40 mL). The organic layers combined, dried 
and concentrated in vacuo to give the crude product as a red oil. The crude material was 
then purified by silica chromatography (0-2% MeOH in EtOAc) to give the title compound as 
a bright red solid (778 mg, 68%). 
νmax (neat): 2924, 2854, 1670, 1630, 1577, 1533, 1437, 1352 cm-1. 1H NMR (400 MHz, 
CDCl3): δ 8.08 (dd, 2H, J = 7.2, 0.8 Hz), 8.02 (dd, 1H, J = 8.4, 1.2 Hz), 7.51 – 7.44 (m, 2H), 
7.42 – 7.36 (m, 3H), 7.33 – 7.26 (m, 3H), 7.15 – 7.11 (m, 1H), 6.98 (d, 1H, J = 6.8 Hz), 6.67 
– 6.60 (m, 2H), 5.92 – 5.82 (m, 1H), 5.11 – 5.01 (m, 2H), 4.51 (d, 1H, J = 13.2 Hz), 3.71 (d, 
1H, J = 12.4 Hz), 3.67 – 3.63 (m, 1H), 3.44 (dd, 1H, J = 6.0, 4.4 Hz), 3.30 – 3.22 (m, 1H), 
2.74 – 2.66 (m, 1H), 2.51 – 2.37 (m, 2H), 2.15 – 2.01 (m, 5H), 1.77 – 1.65 (m, 2H), 1.24 (s, 
3H). 13C NMR (101 MHz, CDCl3 ): 182.4, 180.5, 172.4, 141.5, 137.9, 136.6, 133.3, 131.7, 
131.5, 130.3, 129.4, 129.0, 128.9, 128.7, 127.9, 127.3, 127.0, 124.0, 120.7, 115.4, 78.0, 
70.0, 63.4, 57.0, 39.9, 33.7, 30.7, 29.6, 30.7, 25.3, 23.3. HRMS: (C33H36O3N3Ni) [M+H]+ 
requires 580.2105, found [M+H]+ 580.2095. [α]20D = +1273 (c = 0.03, MeOH). dr = >98% by 
1H NMR. ee = 94% by chiral HPLC, retention time = 12.64 min. 
 
 (R)-Ni(II)-R5-BPB (14) 
To a dry round bottomed flask containing dry THF (150 mL) was added 13 (6.00 g, 11.7 
mmol, 1 equiv.) and cooled to 0 oC under N2. TBAI (433 mg, 1.2 mmol, 0.1 equiv.) and 
sublimed tBuOK (2.63 g, 23.4 mmol, 2 equiv.) were added and the mixture left to stir for 5 
minutes. 5-iodopentene (4.59 g, 23.4 mmol, 2 equiv.) was added dropwise over 5 minutes 
and the reaction mixture left to stir at room temperature for 17 h. The reaction mixture was 
quenched with 0.1 M HCl and separated with DCM (3 x 250 mL). The organic layers 
combined, dried and concentrated in vacuo to give the crude product as a red oil. The crude 
material was then purified by silica chromatography (0-2% MeOH in EtOAc) to give the title 
compound as a bright red solid (4.24 g, 62%). 
νmax (neat): 2968, 2942, 2858, 1664, 1635, 1571, 1533, 1435, 1355 cm-1. 1H NMR (400 MHz, 
CDCl3): δ 8.09 (d, 2H, J = 6.8 Hz), 8.03 (d, 1H, J = 9.2 Hz), 7.51 – 7.48 (m, 2H), 7.44 – 7.40 
(m, 3H), 7.35 – 7.27 (m, 3H), 7.17 – 7.12 (m, 1H), 7.00 (dd, 1H, J = 6.4, 1.2 Hz), 6.68 – 6.62 
(m, 2H), 5.93 – 5.83 (m, 1H), 5.13 – 5.03 (m, 2H), 4.51 (d, 1H, J = 12.4 Hz), 3.72 (d, 1H, J = 
12.4 Hz), 3.69 – 3.64 (m, 1H), 3.45 (dd, 1H, J = 6.0, 4.8 Hz), 3.31 – 3.24 (m, 1H), 2.76 – 
2.68 (m, 1H), 2.53 – 2.39 (m, 2H), 2.19 – 2.03 (m, 5H), 1.79 – 1.69 (m, 2H), 1.25 (s, 3H). 13C 
NMR (101 MHz, CDCl3): 182.2, 180.4, 172.3, 141.4, 136.5, 133.3, 131.7, 131.5, 130.2, 
129.4, 129.0, 128.8, 128.6, 127.8, 127.3, 126.9, 123.9, 120.7, 115.4, 78.0, 69.9, 63.3, 56.9, 
39.8, 33.7, 30.6, 29.5, 25.3, 23.2. HRMS: (C33H36O3N3Ni) [M+H]+ requires 580.2105, found 
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[M+H]+ 580.2099.  [α]20D = -1262 (c = 0.03, MeOH). dr = >98% by 1H NMR. ee = 90% by 
chiral HPLC, retention time = 7.66 min. 
 
 
 (S)-2-amino-2-methylhept-6-enoic acid (11)9 
To a round bottomed flask containing MeOH (13 mL, 0.08 M) was added 10 (583 mg, 1.1 
mmol, 1 equiv.) and 2M HCl (18 mL, 0.06 M). The reaction mixture was heated to reflux for 3 
h turning from a dark red to a yellow solution. The mixture was cooled to room temparature 
and basified to pH 9 with conc. NH3. Water (50 mL) was added and the mixture separated 
with DCM (3 x 100 mL). The aqueous layer was concentrated in vacuo to give a crude 
turquoise solid. 40 g of Dowex resin (50WX8 hydrogen form) was swollen in water and 
packed into a column and washed with water. The crude solid was then dissolved in 
MeOH:water (1:1) and added to the resin. The column was then washed with MeOH (120 
mL) and water (120 mL) to elute impurities. The product was then eluted using 25% NH3 in 
water (200 mL) and concentrated in vacuo. The white solid was then dissolved in water and 
freeze dried to give the title compound as a flocculent white solid (101 mg, 80%). 
νmax (neat): 3053, 2947, 1585, 1539, 1458, 1404 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 7.61 
(br s, 3H), 5.81 - 5.72 (m, 1H), 5.04 – 4.94 (m, 2H), 2.00 – 1.95 (m, 2H), 1.68 – 1.60 (m, 1H), 
1.55  – 1.43 (m, 2H), 1.30 – 1.23 (m, 4H). 13C NMR (101 MHz, DMSO-d6): δ 138.4, 114.8, 
59.7, 37.4, 33.3, 23.2, 22.7 1C not observed (C=O). HRMS: (C8H16O2N) [M+H]+ requires 
158.1176, found [M+H]+ 158.1176. [α]20D = +12 (c = 0.15, MeOH) 
 
(R)-2-amino-2-methylhept-6-enoic acid (15) 
To a round bottomed flask containing MeOH (90 mL, 0.08 M) was added 14 (4.2 g, 7.2 
mmol, 1 equiv.) and 2M HCl (121 mL, 0.06 M). The reaction mixture was heated to reflux for 
3 h turning from a dark red to a yellow solution. The mixture was cooled to r.t and basified to 
pH 9 with conc. NH3. Water (150 mL) was added and the mixture separated with DCM (3 x 
200 mL). The aqueous layer was concentrated in vacuo to give a crude turquoise solid. 40 g 
of Dowex resin (50WX8 hydrogen form) was swollen in water and packed into a column and 
washed with water. The crude solid was then dissolved in MeOH:water (1:1) and added to 
the resin. The column was then washed with MeOH (150 mL) and water (150mL) to elute 
impurities. The product was then eluted using 25% NH3 in water (250 mL) and concentrated 
in vacuo. The white solid was then dissolved in water and freeze dried to give the title 
compound as a flocculent white solid (675 mg, 78%). 
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νmax (neat): 3049, 2980, 2947, 1585, 1458, 1402 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 7.49 
(br s, 3H), 5.82 - 5.72 (m, 1H), 5.04 – 4.94 (m, 2H), 1.20 – 1.94 (m, 2H), 1.68 – 1.60 (m, 1H), 
1.54 – 1.43 (m, 2H), 1.30 – 1.23 (m, 4H). 13C NMR (101 MHz, DMSO-d6): δ 138.4, 114.8, 
59.7, 37.4, 33.3, 23.1, 22.7 1C not observed (C=O). HRMS: (C8H14O2N) [M-H]- requires 
156.1030, found [M-H]- 156.1032. [α]20D = -12 (c = 0.15, MeOH). 
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-methylhept-6-enoic acid (1)9 
 
To a round bottomed flask containing H2O (9 mL) and dioxane (9 mL) was added 11 (170 
mg, 1.10 mmol, 1 equiv.) and Na2CO3 (229 mg, 2.20 mmol, 2 equiv.) to form a cloudy 
solution. The reaction mixture was cooled to 0 oC and 9-Fluorenylmethyl N-succinimidyl 
carbonate (730 mg, 2.20 mmol, 2 equiv.) was added in small portions over 2 h, with the 
reaction temperature being maintained between 0 oC to 5 oC. Once addition was complete 
the reaction was left to stir at r.t for 17 h. The reaction mixture was then concentrated in 
vacuo and the residue separated with water (3 x 100 mL) and Et2O 100 mL). The aqueous 
washings were back extracted with Et2O (100 mL), combined and acidified to pH4 using 1 M 
HCl. The aqueous solution was then extracted with EtOAc (2 x 100 mL) and the organic 
layers washed with 1M HCl (2 x 100 mL). The organic layers combined, dried and 
concentrated in vacuo to give the crude product as a yellow oil. The crude material was then 
purified by silica chromatography (0 - 3% MeOH in DCM) to give the title compound as a 
yellow gummy solid (344 mg, 84%). 
νmax (neat):  2939, 1705, 1641, 1506, 1450 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 7.90 (d, 
2H, J = 7.6 Hz), 7.73 (d, 2H, J = 7.6 Hz), 7.46 – 7.40 (m, 3H), 7.34 (td, 2HJ = 6.8, 0.8 Hz), 
5.83 – 5.73 (m, 1H), 5.03 – 4.95 (m, 2H), 4.28 – 4.19 (m, 3H), 2.01 – 1.97 (m, 2H), 1.78 – 
1.68 (m, 2H), 1.36 – 1.26 (m, 5H). 13C NMR (101 MHz, DMSO-d6): 175.3, 154.7, 143.8, 
140.7, 138.5, 127.6, 127.0, 125.2, 120.0, 114.9, 65.2, 58.2, 46.7, 36.2, 33.2, 22.5, 22.3. 
HRMS: (C23H26O4N) [M+H]+ requires 380.1856, found [M+H]+ 380.1858. [α]20D = +18.1 (c = 
0.15, MeOH). ee = 92% by chiral HPLC, retention time = 9.55 min. 
 (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-methylhept-6-enoic acid (2) 
 
To a round bottomed flask containing H2O (27.5 mL) and dioxane (27.5 mL) was added 15 
(517 mg, 3.30 mmol, 1 equiv.) and Na2CO3 (697 mg, 6.60 mmol, 2 equiv.) to form a cloudy 
solution. The reaction mixture was cooled to 0 oC and 9-Fluorenylmethyl N-succinimidyl 
carbonate (2.2 g, 6.6 mmol, 2 equiv.) was added in small portions over 2 h, with the reaction 
temperature being maintained between 0 oC to 5 oC. Once addition was complete the 
15 
 
reaction was left to stir at r.t for 17 h. The reaction mixture was then concentrated in vacuo 
and the residue separated with water (3 x 200 mL) and Et2O (200 mL). The aqueous 
washings were back extracted with Et2O (200 mL), combined and acidified to pH4 using 1 M 
HCl. The aqueous solution was then extracted with EtOAc (2 x 200 mL) and the organic 
layers washed with 1M HCl (2 x 200 mL). The organic layers combined, dried and 
concentrated in vacuo to give the crude product as a yellow oil. The crude material was then 
purified by silica chromatography (0 -3% MeOH in DCM) to give the title compound as a 
yellow gummy solid (690 mg, 55%). 
νmax (neat):  2939, 1705, 1641, 1504, 1448 cm-1. 1H NMR (400 MHz, DMSO-d6): δ 7.90 (d, 
2H, J = 7.6 Hz), 7.73 (d, 2H, J = 7.6 Hz), 7.42 (dd, 3H, J = 7.6, 7.2), 7.34 (dd, 2H J = 7.6, 
7.2), 5.82 – 5.75 (m, 1H), 5.03 – 4.94 (m, 2H), 4.28 – 4.19 (m, 3H), 2.01 – 1.99 (m, 2H), 1.78 
– 1.69 (m, 2H), 1.36 – 1.26 (m, 5H). 13C NMR (101 MHz, DMSO-d6): 175.4, 154.8, 143.9, 
140.7, 138.4, 127.6, 127.1, 125.3, 120.0, 114.9, 65.2, 58.3, 46.8, 36.2, 33.3, 22.5, 22.4  
HRMS: (C23H26O4N) [M+H]+ requires 380.1856, found [M+H]+ 380.1859.  [α]20D = -13.5  (c = 
0.15, MeOH). ee = 90% by chiral HPLC, retention time = 10.96 min. 
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